These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 19306900

  • 1. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
    Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, Kontermann RE.
    J Control Release; 2009 Jul 01; 137(1):69-77. PubMed ID: 19306900
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K, Sundaresan A, Cheow WS.
    Eur J Pharm Biopharm; 2013 Nov 01; 85(3 Pt A):427-43. PubMed ID: 23872180
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
    Demirgöz D, Garg A, Kokkoli E.
    Langmuir; 2008 Dec 02; 24(23):13518-24. PubMed ID: 18954096
    [Abstract] [Full Text] [Related]

  • 6. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD, Huang L.
    Mol Pharm; 2006 Dec 02; 3(5):579-88. PubMed ID: 17009857
    [Abstract] [Full Text] [Related]

  • 7. Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.
    Schuster L, Seifert O, Vollmer S, Kontermann RE, Schlosshauer B, Hartmann H.
    Mol Pharm; 2015 Sep 08; 12(9):3146-57. PubMed ID: 26181293
    [Abstract] [Full Text] [Related]

  • 8. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug.
    Gerspach J, Müller D, Münkel S, Selchow O, Nemeth J, Noack M, Petrul H, Menrad A, Wajant H, Pfizenmaier K.
    Cell Death Differ; 2006 Feb 08; 13(2):273-84. PubMed ID: 16052236
    [Abstract] [Full Text] [Related]

  • 9. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H.
    J Control Release; 2009 Jul 01; 137(1):8-14. PubMed ID: 19285528
    [Abstract] [Full Text] [Related]

  • 10. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.
    Baum P, Müller D, Rüger R, Kontermann RE.
    J Drug Target; 2007 Jul 01; 15(6):399-406. PubMed ID: 17613658
    [Abstract] [Full Text] [Related]

  • 11. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
    Schroeder JE, Shweky I, Shmeeda H, Banin U, Gabizon A.
    J Control Release; 2007 Dec 04; 124(1-2):28-34. PubMed ID: 17928088
    [Abstract] [Full Text] [Related]

  • 12. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
    Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ.
    Eur J Pharm Sci; 2006 Jan 04; 27(1):27-36. PubMed ID: 16150582
    [Abstract] [Full Text] [Related]

  • 13. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
    McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV.
    Biomaterials; 2009 Aug 04; 30(23-24):3986-95. PubMed ID: 19427688
    [Abstract] [Full Text] [Related]

  • 14. Polymeric nanoparticles for drug delivery.
    Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC.
    Methods Mol Biol; 2010 Aug 04; 624():163-75. PubMed ID: 20217595
    [Abstract] [Full Text] [Related]

  • 15. Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies.
    Debs RJ, Düzgüneş N, Brunette EN, Fendly B, Patton J, Philip R.
    J Immunol; 1989 Aug 15; 143(4):1192-7. PubMed ID: 2787358
    [Abstract] [Full Text] [Related]

  • 16. A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery.
    Xu Y, Jin X, Ping Q, Cheng J, Sun M, Cao F, You W, Yuan D.
    J Control Release; 2010 Sep 15; 146(3):299-308. PubMed ID: 20580913
    [Abstract] [Full Text] [Related]

  • 17. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY.
    Bioconjug Chem; 2007 Sep 15; 18(1):41-9. PubMed ID: 17226956
    [Abstract] [Full Text] [Related]

  • 18. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.
    Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N, Park JW, Marks JD, Benz CC, Kirpotin DB.
    Mol Pharm; 2006 Sep 15; 3(6):726-36. PubMed ID: 17140260
    [Abstract] [Full Text] [Related]

  • 19. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes.
    Barauskas J, Cervin C, Jankunec M, Spandyreva M, Ribokaite K, Tiberg F, Johnsson M.
    Int J Pharm; 2010 May 31; 391(1-2):284-91. PubMed ID: 20214966
    [Abstract] [Full Text] [Related]

  • 20. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity.
    Kircheis R, Ostermann E, Wolschek MF, Lichtenberger C, Magin-Lachmann C, Wightman L, Kursa M, Wagner E.
    Cancer Gene Ther; 2002 Aug 31; 9(8):673-80. PubMed ID: 12136428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.